MAPT and Alzheimer disease: A recent phase 2 clinical trial showed that a 24‐week treatment with p38α‐MAPK inhibitor decreased tau proteins in the cerebral spinal fluid of mild AD patients; although it did not improve the cognitive function (Prins et al., 2021).